FMS
NYSE Fresenius Medical Care AG Sponsored ADR$22.24 ↓ -0.14 (-0.63%) Trading Down from the previous close of $22.38, $0.18 below the day’s high of $22.42
- YTD change
- -6.63%
- vs 20-day SMA
- -1.15%
- vs 200-day SMA
- -3.47%
Price ranges
Price & Performance
+0.03 (+0.13%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 61.6% away from all-time highs of $57.94
- FMS is down 7% since the beginning of the year
- FMS is down 16% over the past 12 months
- FMS is down 2% over the past 1 month
- 1% of all FMS investors are betting against FMS
- Number of investors short FMS has gone down 1% versus last month
FMS reads not so good: price sits below both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is -15.9%.
- Previous minute
- -$0.01
- Last hour
- -$0.01
- Last 5 days
- -0.76%
- vs 8-day SMA
- -1.03%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
